Patient-Focused Drug Development: US FDA’s Guidance Development Effort Passes The Mid-Point
Agency has issued two of four methodological draft guidances required under 21st Century Cures Act and convened workshops on the two documents still to come; industry, patient groups applaud FDA’s initiative but point to gaps in the guidance series, particularly around interactions with the agency on patient experience data and approaches to collecting patient preference information.
You may also be interested in...
The International Council for Harmonisation wants to ensure that methods used to collect and integrate patient views into drug development and regulatory decision-making follow agreed standards.
US FDA staffing problems and patient engagement enhancements will be listed as priorities during reauthorization kick-off meeting.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.